低HER2表达性卵巢癌对trastuzumab deruxtecan的反应,一个病例报告

相关实验视频

Updated: Jul 7, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Peter G Rose1

  • 1Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, A-81, 9500 Euclid Ave., Cleveland, OH 44195, USA.

Gynecologic oncology reports
|December 21, 2023
PubMed
概括

再发性卵巢癌的治疗选择有限. 一名患有HER2 1+ IHC和负FISH放大度的患者获得了对trastuzumab deruxtecan的持久部分反应,这表明了对HER2表达性卵巢癌的潜在新疗法.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.7K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K